GB201800620D0 - C3b Binding Polypeptide - Google Patents

C3b Binding Polypeptide

Info

Publication number
GB201800620D0
GB201800620D0 GBGB1800620.5A GB201800620A GB201800620D0 GB 201800620 D0 GB201800620 D0 GB 201800620D0 GB 201800620 A GB201800620 A GB 201800620A GB 201800620 D0 GB201800620 D0 GB 201800620D0
Authority
GB
United Kingdom
Prior art keywords
binding polypeptide
polypeptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1800620.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Priority to GBGB1800620.5A priority Critical patent/GB201800620D0/en
Publication of GB201800620D0 publication Critical patent/GB201800620D0/en
Priority to EP19701065.5A priority patent/EP3740498A1/en
Priority to PCT/EP2019/050949 priority patent/WO2019138137A1/en
Priority to JP2020538949A priority patent/JP7505980B2/ja
Priority to US16/962,108 priority patent/US11524050B2/en
Priority to CN202411057957.XA priority patent/CN119120483A/zh
Priority to AU2019207457A priority patent/AU2019207457B2/en
Priority to CA3088476A priority patent/CA3088476A1/en
Priority to EP24213690.1A priority patent/EP4512822A3/en
Priority to CN201980016721.2A priority patent/CN111788219A/zh
Priority to US18/048,303 priority patent/US12544423B2/en
Priority to US18/052,768 priority patent/US12383600B2/en
Priority to AU2024203142A priority patent/AU2024203142B2/en
Priority to JP2024096034A priority patent/JP2024123077A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB1800620.5A 2018-01-15 2018-01-15 C3b Binding Polypeptide Ceased GB201800620D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1800620.5A GB201800620D0 (en) 2018-01-15 2018-01-15 C3b Binding Polypeptide
CN201980016721.2A CN111788219A (zh) 2018-01-15 2019-01-15 C3b结合多肽
AU2019207457A AU2019207457B2 (en) 2018-01-15 2019-01-15 C3b binding polypeptide
EP24213690.1A EP4512822A3 (en) 2018-01-15 2019-01-15 C3b binding polypeptide
JP2020538949A JP7505980B2 (ja) 2018-01-15 2019-01-15 Ｃ３ｂ結合ポリペプチド
US16/962,108 US11524050B2 (en) 2018-01-15 2019-01-15 C3B binding polypeptide
CN202411057957.XA CN119120483A (zh) 2018-01-15 2019-01-15 C3b结合多肽
EP19701065.5A EP3740498A1 (en) 2018-01-15 2019-01-15 C3b binding polypeptide
CA3088476A CA3088476A1 (en) 2018-01-15 2019-01-15 C3b binding polypeptide
PCT/EP2019/050949 WO2019138137A1 (en) 2018-01-15 2019-01-15 C3b binding polypeptide
US18/048,303 US12544423B2 (en) 2018-01-15 2022-10-20 C3b binding polypeptide
US18/052,768 US12383600B2 (en) 2018-01-15 2022-11-04 C3B binding polypeptide
AU2024203142A AU2024203142B2 (en) 2018-01-15 2024-05-13 C3b binding polypeptide
JP2024096034A JP2024123077A (ja) 2018-01-15 2024-06-13 Ｃ３ｂ結合ポリペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1800620.5A GB201800620D0 (en) 2018-01-15 2018-01-15 C3b Binding Polypeptide

Publications (1)

Publication Number Publication Date
GB201800620D0 true GB201800620D0 (en) 2018-02-28

Family

ID=61256254

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1800620.5A Ceased GB201800620D0 (en) 2018-01-15 2018-01-15 C3b Binding Polypeptide

Country Status (8)

Country Link
US (3) US11524050B2 (enExample)
EP (2) EP3740498A1 (enExample)
JP (2) JP7505980B2 (enExample)
CN (2) CN111788219A (enExample)
AU (2) AU2019207457B2 (enExample)
CA (1) CA3088476A1 (enExample)
GB (1) GB201800620D0 (enExample)
WO (1) WO2019138137A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021081395A1 (en) * 2019-10-23 2021-04-29 Gemini Therapeutics Inc. Methods for treating patients having cfh mutations with recombinant cfh proteins
GB202006789D0 (en) 2020-05-07 2020-06-24 Univ Manchester Detection of complement proteins
EP4214515A1 (en) 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
JP2026501750A (ja) 2023-01-05 2026-01-16 コンプリメント・セラピューティクス・リミテッド 補体疾患を処置するための薬剤および方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981481A (en) * 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
DE3600368C1 (de) 1986-01-09 1987-04-02 Goldschmidt Ag Th Trennmittel fuer Polyurethanformteile
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
AU9149791A (en) 1990-12-06 1992-07-08 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
DE69328098T2 (de) 1992-06-24 2000-08-24 Adprotech Plc, Royston Lösliche derivate des complement type-rezeptors (cr1)
GB9301289D0 (en) 1993-01-22 1993-03-17 Smithkline Beecham Plc Novel composition
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU4452100A (en) 1999-04-09 2000-11-14 Washington University Modified complement system regulators
EP1218409A2 (en) 2000-03-13 2002-07-03 St. Vincent's Hospital (Melbourne) Limited Factor-h related protein 5 (fhr-5) and antibodies thereto
US20030086940A1 (en) 2001-08-10 2003-05-08 Cristina Costa Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
AU2003282724B2 (en) 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
US20060140939A1 (en) 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2004075838A2 (en) 2003-02-21 2004-09-10 Rikshospitalet-Radiumhospitalet Hf Method and compositions for the treatment of meconium aspiration syndrome
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US20050112139A1 (en) 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
JP2005211063A (ja) 2004-01-30 2005-08-11 Junko Maekuroshima ブレンドノニ茶
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20050277158A1 (en) 2004-06-10 2005-12-15 Ge Chen Method and kit for donor specific complement-fixing antibodies crossmatch
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
EP1879610A1 (en) 2005-05-06 2008-01-23 Laboratoires Serono S.A. Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases
JP5219819B2 (ja) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
WO2008005455A2 (en) 2006-07-03 2008-01-10 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
EP2479284B1 (en) 2006-07-13 2017-09-20 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
CA2666843C (en) 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
GB0701213D0 (en) 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
JP5332064B2 (ja) 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
GB2447696A (en) 2007-03-23 2008-09-24 Univ Exeter Photonic biosensor arrays
GB2447698A (en) 2007-03-23 2008-09-24 Univ Exeter Fabrication of photonic biosensor arrays
RU2473563C2 (ru) * 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
WO2009022246A1 (en) 2007-08-10 2009-02-19 Koninklijke Philips Electronics N.V. Sensor array for spr-based detection.
WO2009059321A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010027872A1 (en) 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis
GB0815576D0 (en) 2008-08-28 2008-10-01 Lucas & Co Analysis of glycated proteins
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
ES2615732T3 (es) 2010-03-01 2017-06-08 Alexion Pharmaceuticals, Inc. Composiciones para tratar la enfermedad de Degos
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011130844A1 (en) 2010-04-22 2011-10-27 Patricia Marlen Nieva Method and apparatus for an interferometric localized surface plasmon resonance (ilspr) sensor
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
AU2011301996A1 (en) 2010-09-15 2013-03-21 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
BR112013010769A2 (pt) 2010-11-01 2019-09-24 Genentech Inc predição de progressão para degeneração macular relacionada à idade avançada usando um escore poligênico
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
HK1218300A1 (zh) 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
GB201301632D0 (en) 2013-01-30 2013-03-13 Imp Innovations Complement System
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
WO2014194213A1 (en) 2013-05-30 2014-12-04 University Of Iowa Research Foundation Specific complement proteins and efficacy of antibody therapy
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
CN104231085B (zh) 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
GB201318170D0 (en) 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
FR3015484A1 (fr) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
US20180085391A1 (en) 2014-08-08 2018-03-29 Modernatx, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
CN107074939B (zh) 2014-08-20 2021-09-07 桑昆血液供给基金会 H因子增强抗体及其用途
WO2016068616A1 (ko) 2014-10-29 2016-05-06 차의과학대학교 산학협력단 C3 또는 c1r 보체를 분비하는 태반 유래 세포 및 이를 포함하는 조성물
US20210318287A1 (en) 2015-02-16 2021-10-14 The Regents Of The University Of Michigan Localized surface plasmon resonance sensor systems and methods
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CN108291216B (zh) * 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
KR20240005973A (ko) 2016-04-15 2024-01-12 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
US11442067B2 (en) 2017-07-25 2022-09-13 Biocon Limited Peptide mapping method for sequence identification of insulin and insulin analogues
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
WO2019215330A1 (en) 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration
CA3100071A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
GB201821082D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
KR20220019806A (ko) 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
GB202006789D0 (en) 2020-05-07 2020-06-24 Univ Manchester Detection of complement proteins
GB202007353D0 (en) 2020-05-18 2020-07-01 Shaw Andrew Viral infection characterization
US20210373009A1 (en) 2020-05-28 2021-12-02 University Of North Texas Plasmonic meta-surface based molecular sensors and methods for making and using them
CR20230202A (es) 2020-10-16 2023-06-13 Gyroscope Therapeutics Ltd Ácido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneración macular relacionada con la edad

Also Published As

Publication number Publication date
CA3088476A1 (en) 2019-07-18
EP3740498A1 (en) 2020-11-25
US20230321184A1 (en) 2023-10-12
EP4512822A3 (en) 2025-04-30
JP2024123077A (ja) 2024-09-10
JP2021511030A (ja) 2021-05-06
WO2019138137A1 (en) 2019-07-18
AU2019207457B2 (en) 2024-02-15
US20210145933A1 (en) 2021-05-20
CN119120483A (zh) 2024-12-13
CN111788219A (zh) 2020-10-16
US11524050B2 (en) 2022-12-13
EP4512822A2 (en) 2025-02-26
US20230310545A1 (en) 2023-10-05
AU2024203142B2 (en) 2026-02-05
AU2024203142A1 (en) 2024-06-06
US12383600B2 (en) 2025-08-12
AU2019207457A1 (en) 2020-08-27
JP7505980B2 (ja) 2024-06-25
US12544423B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
IL272064A (en) Binding proteins 1
IL276730A (en) GAN-CNN for MHC peptide binding prediction
GB201802201D0 (en) Binding agents
IL289122A (en) polypeptides
GB201800620D0 (en) C3b Binding Polypeptide
IL283803A (en) binds peptides
GB201719557D0 (en) Polypeptide
IL289119A (en) polypeptides
GB201709222D0 (en) C3b Inactivating Polypeptide
GB201802338D0 (en) Antigen binding proteins
GB201820556D0 (en) Novel polypeptides
IL304317A (en) tgf–beta–rii binding proteins
SG11202106393SA (en) Pseudofab-based multispecific binding proteins
GB201804094D0 (en) ERBB3 Binding agents
IL269477A (en) Polypeptides that bind to IL-1R-1
SG11202102378WA (en) Arginase1 polypeptides
GB201810052D0 (en) Polypeptide
GB201808868D0 (en) Binder
GB201817810D0 (en) Modified factor IX polypeptides
EP3750824C0 (en) BINDING DEVICE
GB201801959D0 (en) Binding polypeptides
GB201819584D0 (en) Bifunctional binding polypeptide
GB201901704D0 (en) Binding polypeptides
GB201807767D0 (en) Bifunctional binding polypeptide
GB201919286D0 (en) Binding proteins

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)